Skip to main content
Premium Trial:

Request an Annual Quote

Moffitt Cancer Center's M2Gen Joins ConvergeHealth in Personalized Cancer Partnership

NEW YORK (GenomeWeb News) – Moffitt Cancer Center's subsidiary M2Gen has joined Deloitte's ConvergeHealth in a partnership aimed at using analytics and Moffitt's biomarker data to develop personalized cancer treatments, Deloitte said today.

M2Gen, ConvergeHealth, and Deloitte will work together in a consortium launched by Intermountain Healthcare to contribute to biomarker discovery and genetic clinical trial matching, and to generate evidence to support personalized medicine efforts.

The partners will use ConvergeHealth's OutcomesMiner solution, informatics, and consulting services, along with M2Gen's and Moffitt's expertise to conduct personalized medicine studies.

M2Gen is based on Moffitt Cancer Center's Total Cancer Care program. It analyzes patient tissue and information and deposits those clinical and molecular data into a repository that is used for biomarker studies and to support gene-based clinical trials.

"Through our data on biomarkers and ConvergeHEALTH's analytics, this collaboration will help us work toward our goal of personalized cancer care for our patients," said Moffitt Cancer Center's President and CEO Alan List.